XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 6,057 | $ 5,494 | $ 17,945 | $ 16,159
United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 4,571 | 4,109 | 13,565 | 12,070
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,486 | 1,385 | 4,380 | 4,089
MedSurg and Neurotechnology: |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 3,803 | 3,324 |  |
MedSurg and Neurotechnology: | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 2,983 | 2,585 | 8,728 | 7,473
MedSurg and Neurotechnology: | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 820 | 739 | 2,357 | 2,163
MedSurg and Neurotechnology: | Instruments |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 760 | 679 | 2,258 | 2,044
MedSurg and Neurotechnology: | Instruments | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 606 | 544 | 1,814 | 1,640
MedSurg and Neurotechnology: | Instruments | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 154 | 135 | 444 | 404
MedSurg and Neurotechnology: | Endoscopy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 896 | 837 | 2,662 | 2,383
MedSurg and Neurotechnology: | Endoscopy | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 743 | 689 | 2,195 | 1,948
MedSurg and Neurotechnology: | Endoscopy | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 153 | 148 | 467 | 435
MedSurg and Neurotechnology: | Medical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 985 | 938 | 2,920 | 2,710
MedSurg and Neurotechnology: | Medical | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 827 | 783 | 2,469 | 2,261
MedSurg and Neurotechnology: | Medical | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 158 | 155 | 451 | 449
MedSurg and Neurotechnology: | Vascular |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 525 | 329 | 1,429 | 966
MedSurg and Neurotechnology: | Vascular | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 283 | 121 | 754 | 369
MedSurg and Neurotechnology: | Vascular | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 242 | 208 | 675 | 597
MedSurg and Neurotechnology: | Neuro Cranial |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 637 | 541 | 1,816 | 1,533
MedSurg and Neurotechnology: | Neuro Cranial | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 524 | 448 | 1,496 | 1,255
MedSurg and Neurotechnology: | Neuro Cranial | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 113 | 93 | 320 | 278
Orthopaedics: |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 2,254 | 2,170 | 6,860 | 6,523
Orthopaedics: | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,588 | 1,524 | 4,837 | 4,597
Orthopaedics: | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 666 | 646 | 2,023 | 1,926
Orthopaedics: | Knees |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 628 | 570 | 1,907 | 1,760
Orthopaedics: | Knees | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 452 | 417 | 1,376 | 1,279
Orthopaedics: | Knees | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 176 | 153 | 531 | 481
Orthopaedics: | Hips |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 457 | 420 | 1,366 | 1,241
Orthopaedics: | Hips | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 279 | 256 | 831 | 768
Orthopaedics: | Hips | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 178 | 164 | 535 | 473
Orthopaedics: | Trauma and Extremities |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 960 | 849 | 2,862 | 2,511
Orthopaedics: | Trauma and Extremities | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 703 | 621 | 2,118 | 1,842
Orthopaedics: | Trauma and Extremities | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 257 | 228 | 744 | 669
Orthopaedics: | Spinal Implants |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 6 | 172 | 177 | 521
Orthopaedics: | Spinal Implants | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 0 | 119 | 118 | 361
Orthopaedics: | Spinal Implants | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 6 | 53 | 59 | 160
Orthopaedics: | Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 203 | 159 | 548 | 490
Orthopaedics: | Other | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 154 | 111 | 394 | 347
Orthopaedics: | Other | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 49 | $ 48 | $ 154 | $ 143

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_MedSurgAndNeurotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_EndoscopyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeurovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeuroCranialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_OrthopaedicsAndSpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_KneesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_HipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_TraumaandExtremitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_OtherOrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |